Insight

Erman Akkus: 2 studies from JAMA and Thyroid Journal

Photo of Erman Akkus taken from mn.uio.no

Apr 16, 2024, 10:57

Erman Akkus: 2 studies from JAMA and Thyroid Journal

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

1.” Second primary breast cancer among young (≤40 yr) stage 0-III breast cancer survivors: a study of JAMA.

At median 10 years:

2.2% for women who did not carry a germline pathogenic variant;
8.9% for carriers of a pathogenic variant;
PV (pathogenic variant) carriers vs non carriers sHR (sub-hazard ratio): 5.27( 1.43-19.43).

Importance of germ line genetic testing in young women with breast cancer!”

Erman Akkus: 2 studies from JAMA and Thyroid Journal

Source: Erman Akkus/X

2. ”Pembrolizumabin addition to Dabrafenib/Trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma: a study by Thyroid Journal.

Pembrolizumab added upfront or at progression vs dabra-trame alone:

mOS: 17 vs 9 mo, p=0.03
mPFS: 11 vs 4 mo, p=0.04

If dabra-trame given as neoadjuvant (before surgery), mOS: 63 mo.”

Source: Erman Akkus/X

Ankara University Breast Cancer cancer Cancer research cancer survivors Erman Akkus JAMA OncoDaily Oncology pembrolizumab thyroid carcinoma Thyroid Journal

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Special Coverage